57 results on '"Koschmieder, Steffen"'
Search Results
2. Bone marrow biopsy in geriatric patients above the age of 85 years: invaluable or unnecessary? A retrospective analysis
3. Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms
4. Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms
5. Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial
6. Correction: Quantification of hematopoietic stem and progenitor cells by targeted DNA methylation analysis
7. Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group
8. Quantification of hematopoietic stem and progenitor cells by targeted DNA methylation analysis
9. Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model
10. Essenzielle Thrombozythämie und Polycythaemia vera
11. Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)
12. Breakthrough infections in MPN-COVID vaccinated patients
13. Clonogenic assays improve determination of variant allele frequency of driver mutations in myeloproliferative neoplasms
14. Towards personalized medicine with iPS cell technology: a case report of advanced systemic mastocytosis with associated eosinophilia
15. 61/w mit Blutungen und Thrombose bei Thrombozytose
16. Second versus first wave of COVID-19 in patients with MPN
17. Early and late stage MPN patients show distinct gene expression profiles in CD34+ cells
18. Long-term follow-up of recovered MPN patients with COVID-19
19. Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients
20. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
21. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
22. Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm
23. Inflammatory Responses of Astrocytes Are Independent from Lipocalin 2
24. Dexamethasone nanomedicines for COVID-19
25. Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia
26. Correction: Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study
27. Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study
28. Transcriptional alteration of DNA repair genes in Philadelphia chromosome negative myeloproliferative neoplasms
29. Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms
30. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
31. Hematopoietic stem and progenitor cell proliferation and differentiation requires the trithorax protein Ash2l
32. Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha
33. Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)
34. Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling
35. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation
36. Biobankinganforderungen aus Sicht des Klinikers
37. A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
38. Mutant NRAS Q61K is responsible for MAPK pathway activation in the MARIMO cell line and renders these cells independent of the CALR–MPL–JAK2–STAT5 pathway
39. Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita
40. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
41. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey
42. Intramolecular hydrophobic interactions are critical mediators of STAT5 dimerization
43. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion
44. Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia
45. Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH)
46. Myeloproliferative Neoplasien
47. Vorteil für allogene Stammzelltransplantation
48. Epigenetic Biomarker to Support Classification into Pluripotent and Non-Pluripotent Cells
49. Drug Target Optimization in Chronic Myeloid Leukemia Using Innovative Computational Platform
50. Activated fibronectin-secretory phenotype of mesenchymal stromal cells in pre-fibrotic myeloproliferative neoplasms
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.